Back to results
US 6,720,319 B2Granted
Compounds useful as reversible inhibitors of cysteine proteases
AssigneeBoehringer Ingelheim Pharmaceuticals, Inc.
InventorsWeimin Liu, Denice M. Spero, David S. Thomson, Yancey D. Ward, Erick R. R. Young
Life of this patent
Estimating the term…
Abstract
Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
Claims16
A compound of the formula (Ia):
- wherein for the Formula (Ia), the components
- is chosen from A1-A21 in the table below;
- is chosen from B1-B35 in the table below and
- is chosen from C1-C9 in the table below;
- A A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13 A14 A15 A16 A17 A18 A19 A20 A21 B B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27 B28 B29 B30 B31 B32 B33 B34 B35 B35 C C1 C2 C3 C4 C5 C6 C7 C8 C9
- or the pharmaceutically acceptable salts, esters, tautomers, individual isomers and mixtures of isomers thereof.
3 more elements
A compound where the compound is:
- ({1-[4-Cyano-1-(2-morpholin-4-yl-ethyl)-piperidin-4-ylcarbamoyl]-2-cyclohexyl-ethylamino}-morpholin-4-yl-methylene)-carbamic acid isobutyl ester;
- or the pharmaceutically acceptable salts, esters, tautomers, individual isomers and mixtures of isomers thereof.
Dependencies are inferred from the claim text.